Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales.

November 6, 2024Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $1.37, expectations were $0.14.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent BioSolutions Inc. is heading into its next chapter — or “turnaround” phase, as its CEO describes it — after a strong ...

The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face rising death rates.

Emergent BioSolutions (EBS) is up 36.1%, or $3.32 to $12.52. Published first on TheFly – the ultimate source for real-time, ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

Trump to win Wisconsin at 52%. Republicans to win the White House, House, and Senate at 47%. After that post, I added a few ...

At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc. earnings conference call. All lines ...